Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.
about
Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysisMetabolic syndrome in antipsychotic naïve patients with schizophrenia: pooled analysis of data from three Indian studies.Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis.Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams.Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia.Cost-effectiveness of health promotion targeting physical activity and healthy eating in mental health care.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit.Metabolic syndrome among patients receiving clozapine: A preliminary estimate.Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled tCardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.Non-psychiatric health problems among psychiatric inpatients with intellectual disabilitiesCost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.Health promotion in individuals with mental disorders: a cluster preference randomized controlled trialThe prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Association of metabolic syndrome with schizophreniaPerceptions of mental health nurses and patients about health promotion in mental health care: a literature review.The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness.Lipid effects of psychiatric medications."First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects.Implementing and maintaining nurse-led healthy living programs in forensic inpatient settings: an illustrative case study.Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference.Emerging role of sertindole in the management of schizophrenia.Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context.Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme.Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report.Health promotion in mental health care: perceptions from patients and mental health nurses.Metabolic syndrome: differences between psychiatric and internal medicine patients.Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study.
P2860
Q28066750-5C979667-0FA8-43B4-966C-57A7884AA7DCQ30736365-88B964E1-1FFD-4F13-B936-C04BC5676E77Q33371995-B33844E8-246D-469F-B00F-95CBF19E39C5Q33539405-8F03B02E-DFD1-4ECF-B84F-CCFDFF0267AFQ33737076-E208141D-739B-45AB-8DBE-F35C7AEEFD4BQ33968686-91A5265D-D30D-4739-B794-71794EE7EB4DQ34116503-8808CCAF-1070-4A4B-9A98-6CAFE223657FQ34623350-5DB45996-FEFF-4590-971F-2F244D3DC510Q34786258-DF36E082-ED66-4703-BF34-ACEFE38C1389Q35365361-9EDF90B5-6D60-4778-A11B-373649CC8B4FQ36574892-8D61385C-E662-40AC-8382-81B42E97EAD6Q36714070-F1DB4DB0-FCC8-437B-9BE2-6AA106C0BC26Q36822223-A06E2553-3319-467C-B79A-91966876B4E4Q36990173-9CFBC81A-9600-4111-B325-B9A8F61504B9Q37016538-3724504B-BED4-41ED-A78A-7074EF6C9C89Q37042160-4F2391C9-89E6-4EEF-80AD-1F4010A78A4AQ37079080-19B8A15B-5AB7-4530-950A-F17A42BA46E5Q37201683-A2491CFB-87C6-4843-B071-918FACC6DB27Q37900351-BD58762B-FE8D-4745-ABF8-20B76F74C5B3Q37920920-BD8B042A-F8C1-4A92-ACE2-7334FEEB1AE5Q38066118-591E505A-5175-4D66-BB65-10555C43EA09Q38291338-D6AD4661-0A45-4763-A176-626051B0825CQ39740943-6FE0C532-6B46-4118-9E96-5251F4BDDAAAQ40119718-CDB5D7DF-8F2B-44AB-8660-ADB8C8BBCC89Q42427678-016EA3D5-5801-4C02-BF0A-5E136DAF68D5Q43205612-AFC62158-1CD2-4FBD-A601-A2DDC18C339AQ46110645-00AFA9DA-EFA6-4FB8-B4D1-DF4CCDD60753Q46517338-C5E6E74B-9E57-4D68-9D7A-3738D16F695AQ47121019-5E70BBFE-4A7C-4E18-884A-FACA4516613CQ47926964-1C32C02B-9B77-4240-82B3-83BEA7CCA9B0Q48422028-968BDD27-024F-43B5-9AE7-9B8991021B89Q55423163-C973EDD9-5BD7-457C-9FD3-D75420355A1B
P2860
Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Metabolic disease and cardiova ...... tipsychotics in the community.
@en
Metabolic disease and cardiova ...... tipsychotics in the community.
@nl
type
label
Metabolic disease and cardiova ...... tipsychotics in the community.
@en
Metabolic disease and cardiova ...... tipsychotics in the community.
@nl
prefLabel
Metabolic disease and cardiova ...... tipsychotics in the community.
@en
Metabolic disease and cardiova ...... tipsychotics in the community.
@nl
P2093
P1476
Metabolic disease and cardiova ...... tipsychotics in the community.
@en
P2093
David Bishop
Helen Watkinson
I Nicol Ferrier
Paul Mackin
Peter Gallagher
P356
10.1192/BJP.BP.106.031716
P407
P577
2007-07-01T00:00:00Z